Literature DB >> 10456763

Rett syndrome: 1H spectroscopic imaging at 4.1 Tesla.

J W Pan1, J B Lane, H Hetherington, A K Percy.   

Abstract

Rett syndrome, a neurodevelopmental disorder predominantly affecting girls, is characterized by regression of psychomotor development, communication dysfunction, and hand stereotypies. Brain morphologic studies demonstrate increased neuronal packing density and reduced dendritic arborizations, suggesting an arrest or interruption of normal maturation. Numerous neurotransmitter systems have been implicated. Among these, cerebrospinal fluid glutamate levels are elevated and glutamate receptors, particularly in putamen, are reduced. Therefore, 1H spectroscopy at 4.1 Tesla was used to evaluate glutamate, creatine, and N-acetylaspartate in six girls with Rett syndrome and four normal sibling controls. The ratio of creatine to N-acetylaspartate was significantly elevated in white matter, primarily reflecting reduced N-acetylaspartate levels, and normal in gray matter. The glutamate to N-acetylaspartate ratio was elevated in gray matter and normal in white matter. These findings are consistent with previous neuropathologic and neurochemical findings and indicate the feasibility of imaging these metabolites in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456763     DOI: 10.1177/088307389901400808

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  22 in total

Review 1.  Imaging of neurogenetic and neurometabolic disorders of childhood.

Authors:  Andrea Gropman
Journal:  Curr Neurol Neurosci Rep       Date:  2004-03       Impact factor: 5.081

Review 2.  Rett syndrome and other autism spectrum disorders--brain diseases of immune malfunction?

Authors:  N C Derecki; E Privman; J Kipnis
Journal:  Mol Psychiatry       Date:  2010-02-23       Impact factor: 15.992

3.  Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.

Authors:  Christopher A Chapleau; Gaston D Calfa; Meredith C Lane; Asher J Albertson; Jennifer L Larimore; Shinichi Kudo; Dawna L Armstrong; Alan K Percy; Lucas Pozzo-Miller
Journal:  Neurobiol Dis       Date:  2009-05-12       Impact factor: 5.996

Review 4.  Breathing dysfunction in Rett syndrome: understanding epigenetic regulation of the respiratory network.

Authors:  Michael Ogier; David M Katz
Journal:  Respir Physiol Neurobiol       Date:  2008-12-10       Impact factor: 1.931

Review 5.  Glutamate and glutamine: a review of in vivo MRS in the human brain.

Authors:  Saadallah Ramadan; Alexander Lin; Peter Stanwell
Journal:  NMR Biomed       Date:  2013-10-04       Impact factor: 4.044

6.  Regional distributions of brain glutamate and glutamine in normal subjects.

Authors:  Mohammed Z Goryawala; Sulaiman Sheriff; Andrew A Maudsley
Journal:  NMR Biomed       Date:  2016-06-28       Impact factor: 4.044

Review 7.  Experimental models of Rett syndrome based on Mecp2 dysfunction.

Authors:  Gaston Calfa; Alan K Percy; Lucas Pozzo-Miller
Journal:  Exp Biol Med (Maywood)       Date:  2011-01

8.  Altered carbon dioxide metabolism and creatine abnormalities in rett syndrome.

Authors:  Nicky S J Halbach; Eric E J Smeets; Jörgen Bierau; Irene M L W Keularts; Guy Plasqui; Peter O O Julu; Ingegerd Witt Engerström; Jaap A Bakker; Leopold M G Curfs
Journal:  JIMD Rep       Date:  2011-09-28

Review 9.  The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment.

Authors:  Donald C Rojas
Journal:  J Neural Transm (Vienna)       Date:  2014-04-22       Impact factor: 3.575

10.  F2-dihomo-isoprostanes as potential early biomarkers of lipid oxidative damage in Rett syndrome.

Authors:  Claudio De Felice; Cinzia Signorini; Thierry Durand; Camille Oger; Alexandre Guy; Valérie Bultel-Poncé; Jean-Marie Galano; Lucia Ciccoli; Silvia Leoncini; Maurizio D'Esposito; Stefania Filosa; Alessandra Pecorelli; Giuseppe Valacchi; Joussef Hayek
Journal:  J Lipid Res       Date:  2011-09-13       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.